Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af NVL-655 hos patienter med avanceret NSCLC og andre solide tumorer, der rummer ALK-omlejring eller aktiverer ALK-mutation (ALKOVE-1)

4. november 2026 opdateret af: Nuvalent Inc.

Et fase 1/2-studie af den selektive anaplastiske lymfomkinase (ALK)-hæmmer NVL-655 hos patienter med avanceret NSCLC og andre solide tumorer (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.

Phase 1 will evaluate the overall safety and tolerability of neladalkib and will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of neladalkib in patients with advanced ALK+ solid tumors.

Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of neladalkib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of neladalkib in patients with advanced ALK-positive NSCLC and other solid tumors.

A drug-drug interaction (DDI) sub-study will determine the effect of neladalkib on the pharmacokinetics of midazolam and repaglinide, as well as the effect of itraconazole on the pharmacokinetics of neladalkib, in patients with advanced ALK-positive NSCLC

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

In Phase 2, study patients will be enrolled into 6 distinct cohorts:

  • Cohort 2a: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received 1 prior 2nd-generation ALK TKI (ceritinib, alectinib, or brigatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed.
  • Cohort 2b: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received 2-3 prior ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed.
  • Cohort 2c: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received lorlatinib as the only prior ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy received prior to lorlatinib is allowed.
  • Cohort 2d: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who are naïve to ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy is allowed.
  • Cohort 2e: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, not eligible for other Phase 2 cohorts.
  • Cohort 2f: Patients with other solid tumors harboring an ALK rearrangement or activating ALK mutation, who have received ≥1 prior systemic anticancer therapy, or for whom no satisfactory standard therapy exists.

In the DDI sub-study, study patients will be enrolled into 2 distinct cohorts:

  • Cohort G (DDI sub-study with midazolam and repaglinide): Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received ≥1 prior ALK TKI.
  • Cohort H (DDI sub-study with itraconazole): Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received ≥1 prior ALK TKI.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

840

Fase

  • Fase 2
  • Fase 1

Udvidet adgang

Ledig uden for det kliniske forsøg. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • New South Wales
      • Sydney, New South Wales, Australien, 2065
        • Rekruttering
        • Royal North Shore Hospital
        • Ledende efterforsker:
          • Malinda Itchins, MBBS PhD
    • Queensland
      • Woolloongabba, Queensland, Australien, 4102
        • Rekruttering
        • Princess Alexandra Hospital
        • Ledende efterforsker:
          • Kenneth O'Byrne, MD
    • Victoria
      • Melbourne, Victoria, Australien, 3000
        • Rekruttering
        • Peter MacCallum Cancer Centre
        • Ledende efterforsker:
          • Benjamin Solomon, MD, PhD
      • Antwerp, Belgien, 2650
        • Rekruttering
        • Universitair Ziekenhuis Antwerpen (UZA)
        • Ledende efterforsker:
          • Reinier Wener, MD
      • Leuven, Belgien, 3000
        • Rekruttering
        • Universitaire Ziekenhuizen Leuven Campus Gastthuisberg
        • Ledende efterforsker:
          • Christophe Dooms, MD
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Rekruttering
        • Cross Cancer Institute
        • Ledende efterforsker:
          • Quincy Siu Chung Chu, MD
    • British Columbia
      • Vancouver, British Columbia, Canada, VZ 4E6
        • Rekruttering
        • BC Cancer Center
        • Ledende efterforsker:
          • Jamie Feng, MD
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Rekruttering
        • The Ottawa Hospital Cancer Center
        • Ledende efterforsker:
          • Garth Nicholas, MD
      • Toronto, Ontario, Canada, M5G 0A3
        • Rekruttering
        • Princess Margaret Cancer Centre
        • Ledende efterforsker:
          • Geoffrey Liu, M.D.
      • Edinburgh, Det Forenede Kongerige, EH4 2XU
        • Rekruttering
        • Edinburgh Cancer Centre
        • Ledende efterforsker:
          • Colin Barrie, MD
      • London, Det Forenede Kongerige, SM2 5PT
        • Rekruttering
        • The Royal Marsden - Chelsea
        • Ledende efterforsker:
          • Sanjay Popat MD
      • Manchester, Det Forenede Kongerige, M20 4BX
        • Rekruttering
        • The Christie NHS Foundation Trust
        • Ledende efterforsker:
          • Matthew Krebs, MB ChB PhD
    • Surrey
      • Sutton, Surrey, Det Forenede Kongerige, SM2 5PT
        • Rekruttering
        • Royal Marsden Hospital
        • Ledende efterforsker:
          • Sanjay Popat MD
    • California
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • University of California Irvine Medical Center
        • Ledende efterforsker:
          • Misako Nagasaka, MD
      • Sacramento, California, Forenede Stater, 95817
        • Rekruttering
        • University of California, Davis Comprehensive Cancer Center
        • Ledende efterforsker:
          • Jonathan Riess, MD
      • Stanford, California, Forenede Stater, 94305
        • Rekruttering
        • Stanford Cancer Institute
        • Ledende efterforsker:
          • Joel Neal, MD, PhD
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • University of Colorado Cancer Center
        • Ledende efterforsker:
          • Ross Camidge, MD, PhD
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20007
        • Rekruttering
        • Georgetown University Medical Center
        • Ledende efterforsker:
          • Joshua Reuss, MD
    • Florida
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • University of Miami; Sylvester Cancer Center
        • Ledende efterforsker:
          • Gilberto de Lima Lopes, MD
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Winship Cancer Institute, Emory University
        • Ledende efterforsker:
          • Ticiana Leal, MD
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • University of Chicago Medical Center
        • Ledende efterforsker:
          • Marina Garassino, MD
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21224
        • Rekruttering
        • John Hopkins University
        • Ledende efterforsker:
          • Vincent Lam, MD
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
        • Ledende efterforsker:
          • Jessica Lin, MD
      • Boston, Massachusetts, Forenede Stater, 02215
        • Rekruttering
        • Dana Farber Cancer Institute
        • Ledende efterforsker:
          • Alice Shaw, MD
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Rekruttering
        • Henry Ford Cancer Institute
        • Ledende efterforsker:
          • Bindu Potugari, MD
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63310
        • Rekruttering
        • Washington University School of Medicine Siteman Cancer Center
        • Ledende efterforsker:
          • Saiama Waqar, MD
    • New York
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
        • Ledende efterforsker:
          • Alexander Drilon, MD
      • New York, New York, Forenede Stater, 10016
        • Rekruttering
        • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
        • Ledende efterforsker:
          • Elaine Shum, MD
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27705
        • Rekruttering
        • Duke University Medical Center
        • Ledende efterforsker:
          • Thomas Stinchcombe, MD
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • OSU Brain & Spine Hospital
        • Ledende efterforsker:
          • Logan Roof, MD, MSCR
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • University of Pennsylvania, Abramson Cancer Center
        • Ledende efterforsker:
          • Charu Aggarwal, MD
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Sarah Cannon
        • Ledende efterforsker:
          • Melissa Johnson, MD
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Aktiv, ikke rekrutterende
        • MD Anderson Cancer Center
    • Washington
      • Seattle, Washington, Forenede Stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center
        • Ledende efterforsker:
          • Christina Baik, MD, MPH
      • Lyon, Frankrig, 69373
        • Rekruttering
        • Centre Leon Berard
        • Ledende efterforsker:
          • Aurelie Swalduz, MD
      • Nantes, Frankrig, 44093
        • Rekruttering
        • Chu De Nantes
        • Ledende efterforsker:
          • Elvire Pons-Tostivint, MD, PhD
      • Toulouse, Frankrig, 31059
        • Rekruttering
        • Institut Claudius Regaud
        • Ledende efterforsker:
          • Julien Mazieres, MD, PhD
      • Villejuif, Frankrig, 94805
        • Rekruttering
        • Institute Gustave Roussy
        • Ledende efterforsker:
          • Benjamin Besse, MD, PhD
      • Amsterdam, Holland, 1066 CX
        • Rekruttering
        • The Netherlands Cancer Institute
        • Ledende efterforsker:
          • Adrianus Joop de Langen, MD
      • Groningen, Holland, 9713 GZ
        • Rekruttering
        • University Medical Center Groningen (UMCG)
        • Ledende efterforsker:
          • AJ Van Der Wekken, MD
      • Ancona, Italien, 60126
        • Rekruttering
        • Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto
        • Ledende efterforsker:
          • Rossana Berardi, MD
      • Bari, Italien, 70124
        • Rekruttering
        • IRCCS Istituto Tumori "G. Paolo II"
        • Ledende efterforsker:
          • Domenico Galetta, MD
      • Milan, Italien, 20133
        • Rekruttering
        • Fondazione IRCCS Istituto Nazionale dei Tumori
        • Ledende efterforsker:
          • Sara Cresta, MD
      • Milan, Italien, 20141
        • Rekruttering
        • Instituto Europeo di Oncologia
        • Ledende efterforsker:
          • Gianluca Spitaleri, MD
      • Padova, Italien, 35128
        • Rekruttering
        • Instituto Oncologico Veneto
        • Ledende efterforsker:
          • Giulia Pasello, MD
      • Ravenna, Italien, 48100
        • Rekruttering
        • Ospedale Santa Maria delle Croci
        • Ledende efterforsker:
          • Chiara Bennati, MD
      • Rome, Italien, 00144
        • Rekruttering
        • Regina Elena Institute for Cancer Research
        • Ledende efterforsker:
          • Lorenza Landi, MD
      • Kanagawa, Japan, 2418515
        • Rekruttering
        • Kanagawa Cancer Center
        • Ledende efterforsker:
          • Tetsuro Kondo, MD
      • Okayama, Japan, 7008558
        • Rekruttering
        • Okayama University Hospital
        • Ledende efterforsker:
          • Kiichiro Ninomiya, MD
      • Osaka, Japan, 5898511
        • Rekruttering
        • Kindai University Hospital
        • Ledende efterforsker:
          • Junko Tanizaki, MD
      • Shizuoka, Japan, 4118777
        • Rekruttering
        • Shizuoka Cancer Center
        • Ledende efterforsker:
          • Ryo Ko, MD PhD
      • Tokyo, Japan, 1040051
        • Rekruttering
        • National Cancer Center Hospital
        • Ledende efterforsker:
          • Tatsuya Yoshida, MD
      • Tokyo, Japan, 1358550
        • Rekruttering
        • Cancer Institute Hospital of JFCR
        • Ledende efterforsker:
          • Ryo Ariyasu, MD
      • Wakayama, Japan, 6418510
        • Rekruttering
        • Wakayama Medical University Hospital
        • Ledende efterforsker:
          • Hiroaki Akamatsu, MD, PhD
      • Bellinzona, Schweiz, 6500
        • Rekruttering
        • Istituto Oncologico Svizzera Italiana
        • Ledende efterforsker:
          • Patrizia Froesch, MD
      • Lucerne, Schweiz, 6000
        • Rekruttering
        • Luzerner Kantonsspital
        • Ledende efterforsker:
          • Anna Allemann, MD
    • Singapore
      • Singapore, Singapore, Singapore, 119074
        • Rekruttering
        • National University Hospital
        • Ledende efterforsker:
          • Ross Soo, MD
      • Singapore, Singapore, Singapore, 168583
        • Rekruttering
        • National Cancer Centre Singapore
        • Ledende efterforsker:
          • Aaron Tan, MD
      • A Coruña, Spanien, 15006
        • Rekruttering
        • Complejo Hospitalario Universitario de A Coruna
        • Ledende efterforsker:
          • Maria Campelo, MD
      • Barcelona, Spanien, 08035
        • Rekruttering
        • Vall d'Hebron
        • Ledende efterforsker:
          • Enriqueta Felip, Md, PhD
      • Barcelona, Spanien, 08017
        • Rekruttering
        • UOMI Cancer Center
        • Ledende efterforsker:
          • Santiago Viteri Ramirez, MD PhD
      • Madrid, Spanien, 28041
        • Rekruttering
        • Hospital Universitario 12 de Octubre
        • Ledende efterforsker:
          • Luis Paz Ares, MD, PhD
      • Madrid, Spanien, 28009
        • Rekruttering
        • Hospital General Universitario Gregorio Maranon
        • Ledende efterforsker:
          • Antonio Calles, MD
      • Seoul, Sydkorea, 03080
        • Rekruttering
        • Seoul National University Hospital
        • Ledende efterforsker:
          • Dong-wan Kim, MD
      • Seoul, Sydkorea, 06351
        • Rekruttering
        • Samsung Medical Center
        • Ledende efterforsker:
          • Myung-Ju Ahn, MD
      • Seoul, Sydkorea, 03722
        • Rekruttering
        • Severance Hospital Yonsei University Health System
        • Ledende efterforsker:
          • Byoung Chul Cho, MD
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Sydkorea, 10408
        • Rekruttering
        • National Cancer Center
        • Ledende efterforsker:
          • Ji-Youn Han, MD
      • Taichung, Taiwan, 402306
        • Rekruttering
        • Chung-Shan Medical University Hospital
        • Ledende efterforsker:
          • Gee-Chen Chang, MD
      • Tainan, Taiwan, 70403
        • Rekruttering
        • National Cheng Kung University Hospital
        • Ledende efterforsker:
          • Chien-Chung Lin, MD
      • Taipei, Taiwan, 10002
        • Rekruttering
        • National Taiwan University Hospital
        • Ledende efterforsker:
          • Josh Lin, MD
      • Cologne, Tyskland, 50937
        • Rekruttering
        • Universitatsklinikum Koln - University Hospital Cologne
        • Ledende efterforsker:
          • Dr med Sebastian Michels
      • Frankfurt, Tyskland, 60590
        • Rekruttering
        • Universitätsklinikum Frankfurt
        • Ledende efterforsker:
          • Martin Sebastian, MD
      • Großhansdorf, Tyskland, 22927
        • Rekruttering
        • LungenClinic Grosshansdorf GmbH
        • Ledende efterforsker:
          • Prof Dr Martin Reck
      • Heidelberg, Tyskland, 69126
        • Rekruttering
        • Universkitatsklinikum Heidelberg - University Hospital Heidelberg
        • Ledende efterforsker:
          • Prof Dr med Petros Christopoulos

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 years, Phase 2 Cohort 2f only: Age ≥12 years and weighing >40 kg. DDI sub-study Cohorts G and H only: age 18-60 years, inclusive

  2. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.

  3. Phase 2

    1. Phase 2 Cohorts except 2f: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement
    2. Phase 2 Cohort 2f: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation detected by certified assay.
  4. DDI sub-study cohorts: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement

  5. DDI sub-study cohorts: Must have previously received ≥1 ALK TKI; no prior investigational agents targeting ALK; any number of prior chemotherapy and/or immunotherapy

  6. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1 Phase 2: Must have measurable disease according to RECIST 1.1

  7. Adequate organ function and bone marrow reserve

Exclusion criteria:

  1. Patient's cancer has a known oncogenic driver alteration other than ALK.
  2. Known allergy/hypersensitivity to excipients of NVL-655.
  3. Major surgery within 4 weeks of the study entry
  4. Ongoing or anticancer therapy
  5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Phase 1 dose escalation

Neladalkib (NVL-655) oral daily dosing

Oral Tablet of Neladalkib (NVL-655)

Eksperimentel: Cohort 2a

Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received 1 prior 2nd-generation ALK TKI (ceritinib, alectinib, or brigatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed.

Oral Tablet of Neladalkib (NVL-655)

Eksperimentel: Cohort 2b

Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received 2-3 prior ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed.

Oral Tablet of Neladalkib (NVL-655)

Eksperimentel: Cohort 2c

Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received lorlatinib as the only prior ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy received prior to lorlatinib is allowed.

Oral Tablet of Neladalkib (NVL-655)

Eksperimentel: Cohort 2d

Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who are naïve to ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy is allowed.

Oral Tablet of Neladalkib (NVL-655)

Eksperimentel: Cohort 2e

Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, not eligible for other Phase 2 cohorts.

Oral Tablet of Neladalkib (NVL-655)

Eksperimentel: Cohort 2f

Patients with other solid tumors harboring an ALK rearrangement or activating ALK mutation, who have received ≥1 prior systemic anticancer therapy, or for whom no satisfactory standard therapy exists.

Oral Tablet of Neladalkib (NVL-655)

Eksperimentel: Cohort G (DDI sub-study)

Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received ≥1 prior ALK TKI

Oral Tablet of Neladalkib (NVL-655)

Oral Solution of Midazolam

Oral Tablet of Repaglinide

Eksperimentel: Cohort H (DDI sub-study)

Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received ≥1 prior ALK TKI

Oral Tablet of Neladalkib (NVL-655)

Oral Solution of Itraconazole

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate (ORR) (Phase 2)
Tidsramme: 2-3 years after first patient dosed.

To determine ORR as assessed by BICR

2-3 years after first patient dosed.
Dose limiting toxicities (DLTs) (Phase 1)
Tidsramme: Within the first 21 days of the first neladalkib (NVL-655) dose

Define the dose limiting toxicities (DLTs)

Within the first 21 days of the first neladalkib (NVL-655) dose
Recommended Phase 2 Dose (RP2D) (Phase 1)
Tidsramme: Within 21 days of last patient dosed during escalation

To determine the RP2D

Within 21 days of last patient dosed during escalation
Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 1)
Tidsramme: Approximately 3 years

Incidence and severity of treatment-emergent adverse events (TEAEs)

Approximately 3 years
Area under the curve of repaglinide (Phase 2 DDI sub-study)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the effect of multiple oral doses of neladalkib (NVL-655) on the PK of a single oral dose of repaglinide

Pre-dose and up to 24 hours post-dose
Area under the curve of midazolam (Phase 2 DDI sub-study)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the effect of multiple oral doses of neladalkib (NVL-655) on the PK of a single oral dose of midazolam

Pre-dose and up to 24 hours post-dose
Area under the curve of neladalkib (NVL-655) (Phase 2 DDI sub-study)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the effect of itraconazole on the single oral dose PK of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Maximum plasma concentration, (Cmax) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the maximum plasma concentration (Cmax) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Plasma concentration at the end of the dosing interval (Ctau) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the plasma concentration at the end of the dosing interval (Ctau) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Average plasma concentration (Cavg) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the average plasma concentration (Cavg) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Time of maximum concentration (Tmax) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the time of maximum concentration (Tmax) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Area under the curve at the end of the dosing interval (AUCtau) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the area under the curve at the end of the dosing interval (AUCtau) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Area under the curve from time 0 to 24 (AUC0-24) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the area under the curve from time 0 to 24 (AUC0-24) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Area under the curve from time 0 to infinity (AUCinf) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the area under the curve from time 0 to infinity (AUCinf) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Oral clearance (CL/F) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the oral clearance (CL/F) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Volume of distribution (Vz/F) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the volume of distribution (Vz/F) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Half-life (t1/2) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose

To determine the half-life (t1/2) of neladalkib (NVL-655)

Pre-dose and up to 24 hours post-dose
Objective response rate (ORR) (Phase 1)
Tidsramme: 2-3 years after first patient dosed

Determine ORR as assessed by Investigator

2-3 years after first patient dosed
Duration of response (DOR)
Tidsramme: 2-3 years after first patient dosed

Determine DOR of neladalkib (NVL-655) until radiographic disease progression or death

2-3 years after first patient dosed
Clinical benefit rate (CBR)
Tidsramme: 2-3 years after first patient dosed

Determine CBR of neladalkib (NVL-655)

2-3 years after first patient dosed
Time to response
Tidsramme: Approximately 3 years

Determine time to response of neladalkib (NVL-655)

Approximately 3 years
Progression-free survival (PFS)
Tidsramme: 2-3 years after first patient dosed

Determine PFS of neladalkib (NVL-655) until radiographic disease progression or death

2-3 years after first patient dosed
Overall survival (OS) (Phase 2)
Tidsramme: Approximately 3 years

Determine OS

Approximately 3 years
Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 2)
Tidsramme: Approximately 3 years

Incidence and severity of treatment-emergent adverse events (TEAEs)

Approximately 3 years
Quality of life assessment
Tidsramme: 2-3 years after first patient dosed

Measure the quality of life in patients with cancer and/or lung cancer.

2-3 years after first patient dosed
Incidence and severity of AEs and incidence of abnormalities across laboratory values, ECGs, vital signs, and physical examinations (Phase 2 DDI-sub-study)
Tidsramme: Up to 3 months after last dose

Assess the safety and tolerability of neladalkib (NVL-655) when co-administered with repaglinide or midazolam

Up to 3 months after last dose
Incidence and severity of AEs and incidence of abnormalities across laboratory values, ECGs, vital signs, and physical examinations (Phase 2 DDI-sub-study)
Tidsramme: Up to 3 months after last dose

Assess the safety and tolerability of neladalkib (NVL-655) when co-administered with itraconazole

Up to 3 months after last dose

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Viola Zhu, MD, PHD, Nuvalent Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. juni 2022

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. januar 2028

Datoer for studieregistrering

Først indsendt

17. maj 2022

Først indsendt, der opfyldte QC-kriterier

17. maj 2022

Først opslået (Faktiske)

20. maj 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NVL-655-01

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .